Publications Clinical Highlights: April 2025 Your monthly source for drug information highlights. April 29, 2025 Trending topics Results from the double-blind, placebo-controlled SOUL trial...

Quarterly Drug Pipeline: April 2024 Clinical insights and competitive intelligence on anticipated drugs in development Drug Pipeline Clinical insights and competitive intelligence on anticipated...

Prime/MRx remains at the forefront of GLP-1 research, presenting weight loss studies at this year’s annual meeting.

Lassen, chief clinical officer at Prime Therapeutics/Magellan Rx, shares insights on GLP-1 weight-loss drugs and evidence-based approaches to providing the kind of care we’d want for our loved ones.

Cover for 2023 January Quarterly Pipeline A view into upcoming specialty & traditional drugs Prime Therapeutics https://issuu.com/primetherapeutics/docs/2023_pipeline_jan?fr=sODMzODc3NDc1ODQ About...

Cover for 2023 April Quarterly Pipeline A view into upcoming specialty & traditional drugs Prime Therapeutics https://issuu.com/primetherapeutics/docs/2023_pipeline_apr?fr=xKAE9_zU1NQ About Prime...

Cover for 2023 July Quarterly Pipeline a view into upcoming specialty & traditional drugs Prime Therapeutics https://issuu.com/primetherapeutics/docs/2023_pipeline_jul?fr=sMjFiMTc3NDc1ODQ About...

Cover for 2023 October Quarterly Pipeline A view into upcoming specialty & traditional drugs Prime Therapeutics https://issuu.com/primetherapeutics/docs/2023_pipeline_oct?fr=sMTIyZTc3NDc1ODQ About...

PUBLICATIONS FDA Decisions Expected Drug pipeline for December 2024 November 15, 2024 Your monthly synopsis of new drugs expected to hit the market At Prime Therapeutics (Prime), we have...

publications Quarterly Drug Pipeline: January 2025 Clinical insights and competitive intelligence on anticipated drugs in development January 30, 2025 Editor-in-chief's message Welcome to the Prime...